A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics.

ABSTRACT:

Aims

The aim was to comprehensively investigate the effects of genetic variability on the pharmacokinetics of rosuvastatin.

Methods

We conducted a genome-wide association study and candidate gene analyses of single dose rosuvastatin pharmacokinetics in a prospective study (n = 159) and a cohort of previously published studies (n = 88).

Results

In a genome-wide association meta-analysis of the prospective study and the cohort of previously published studies, the SLCO1B1 c.521 T > C (rs4149056) single nucleotide variation (SNV) associated with increased area under the plasma concentration-time curve (AUC) and peak plasma concentration of rosuvastatin (P = 1.8 × 10^-12 and P = 3.2 × 10^-15 ). The candidate gene analysis suggested that the ABCG2 c.421C

SUBMITTER: Lehtisalo M 

PROVIDER: S-EPMC10087178 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature